Results 121 to 130 of about 5,547 (244)

Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference [PDF]

, 2016
In October 2015, the third international Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference was held in Vienna to foster discussion on challenges in pricing and reimbursement policies for medicines.

core   +1 more source

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

Clinical Pharmacology & Therapeutics
There are no clinically meaningful differences between bio‐originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4 mL/no ...
Amy C.D. Peeters, Maike H.M. Wientjes, Wieland D. Müskens, David F. Ten Cate, Laura C. Coates, Bart J. F. van den Bemt, Noortje van Herwaarden, Alfons A. den Broeder   +7 more
openaire   +1 more source

Immunoteràpia, un concepte clàssic amb novetats rellevants: els biològics i la immunoteràpia antitumoral com a exemples concrets [PDF]

, 2014
De la inducció de memòria immunitària de les vacunes antiinfeccioses, a la immunoteràpia cel·lular i genètica per al tractament de tumors, el ventall de teràpies potencials a través de la modulació del sistema immunitari és una de les aproximacions més ...
Caballero Baños, Miguel, González Navarro, Azucena, Juan, Manel, Yagüe, Jordi   +3 more
core  

Review on lipegfilgrastim

International Journal of Nanomedicine, 2015
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of ...
Gasparic M, Leyman S
doaj  

The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)

Thrombosis Journal, 2017
Recently, the European Medicines Agency (EMA) authorized the introduction and marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin (LMWH) enoxaparin.
Davide Imberti, Marco Marietta, Hernan Polo Friz, Claudio Cimminiello   +3 more
doaj   +1 more source

Limited Options to Manage Specialty Drug Spending [PDF]

, 2012
Outlines rising trends in costs of and spending on specialty drugs; health plans' efforts to curb specialty drug spending, including patient cost sharing and utilization management; and efforts to integrate medical and pharmaceutical ...
Divya R. Samuel, Ha T. Tu
core  

EE551 Impacts on Prices and Expenses with Biological Medicines of the Specialized Component of Pharmaceutical Assistance after the Entry of Biosimilars within the Brazilian Public Health System [PDF]

, 2023
Lindemberg Assunção Costa, Harrison Floriano Nascimento, Carolina Ribeiro Soares, J.F.F. Machado, Raquel Vaz, Luís Silva, Daniela Maria Freire Marinho, Enrique Chaves Peres, Mariane Cardoso Carvalho   +8 more
openalex   +1 more source

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar

ClinicoEconomics and Outcomes Research, 2018
Lee S Schwartzberg,1,2 Lincy S Lal,3 Sanjeev Balu,4 Kim Campbell,4 Lee Brekke,3 Caitlin Elliott,3 Stephanie Korrer3 1West Cancer Center, Memphis, TN, USA; 2Division of Hematology and Oncology, University of Tennessee, Memphis, TN, USA; 3Health Economics ...
Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, Korrer S   +6 more
doaj  

4CPS-144 Establishment of a pharmaceutical standardised interview concerning biosimilars of infliximab in the daycare clinic of a gastroenterology department for patients affected by inflammatory bowel disease [PDF]

, 2019
E Coget, P Laffont-Lozes, V Velasco Gonzalvo, D Huc, Guillaume Pineton de Chambrun, Romain Altwegg, Pierre Blanc, GP Pageaux, D Rosant, Cyril Breuker   +9 more
openalex   +1 more source

Nonclinical Similarity of the Biosimilar Candidate ABP 938 with Aflibercept Reference Product

Ophthalmology and Therapy
Introduction ABP 938 is being developed as a biosimilar to Eylea® (aflibercept reference product [RP]), an anti-vascular endothelial growth factor (VEGF) drug used in the management of retinal diseases.
Neungseon Seo, Scott Kuhns, Dina A. Andrews, Alexander Colbert, Vincent Chow, Jennifer Liu   +5 more
doaj   +1 more source